{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:09:53Z","timestamp":1790003393435,"version":"4.0.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T00:00:00Z","timestamp":1486598400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol Suppl"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s11789-017-0083-2","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T10:05:11Z","timestamp":1486634711000},"page":"12-17","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hyperlipoproteinaemia(a) \u2013 apheresis and emerging therapies"],"prefix":"10.1007","volume":"12","author":[{"given":"Anja","family":"Vogt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,9]]},"reference":[{"key":"83_CR1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","volume":"59","author":"K Berg","year":"1963","unstructured":"Berg K (1963) A new serum type system in man \u2013 the Lp system. Acta Pathol Microbiol Scand 59:369\u2013382","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"26","key":"83_CR2","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","volume":"361","author":"R Clarke","year":"2009","unstructured":"Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M, Consortium P (2009) Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N\u00a0Engl J Med 361(26):2518\u20132528. doi: 10.1056\/NEJMoa0902604","journal-title":"N Engl J Med"},{"issue":"5","key":"83_CR3","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","volume":"63","author":"PR Kamstrup","year":"2014","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG (2014) Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J\u00a0Am Coll Cardiol 63(5):470\u2013477. doi: 10.1016\/j.jacc.2013.09.038","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"83_CR4","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","volume":"301","author":"PR Kamstrup","year":"2009","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG (2009) Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301(22):2331\u20132339. doi: 10.1001\/jama.2009.801","journal-title":"JAMA"},{"issue":"11","key":"83_CR5","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1161\/01.CIR.100.11.1154","volume":"100","author":"F Kronenberg","year":"1999","unstructured":"Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, Egger G, Utermann G, Willeit J (1999) Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 100(11):1154\u20131160","journal-title":"Circulation"},{"issue":"5","key":"83_CR6","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1681\/ASN.V1051027","volume":"10","author":"F Kronenberg","year":"1999","unstructured":"Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Pribasnig A, Meisl T, Konig P, Dieplinger H (1999) The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a\u00a0prospective follow-up. J\u00a0Am Soc Nephrol 10(5):1027\u20131036","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"83_CR7","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/01.ATV.12.10.1214","volume":"12","author":"C Sandholzer","year":"1992","unstructured":"Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, Hoppichler F, Boerwinkle E, Utermann G (1992) Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb 12(10):1214\u20131226","journal-title":"Arterioscler. Thromb"},{"issue":"6","key":"83_CR8","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1161\/01.ATV.16.6.713","volume":"16","author":"HG Kraft","year":"1996","unstructured":"Kraft HG, Lingenhel A, Kochl S, Hoppichler F, Kronenberg F, Abe A, Muhlberger V, Schonitzer D, Utermann G (1996) Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 16(6):713\u2013719","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"83_CR9","doi-asserted-by":"publisher","first-page":"NP1-NP96","DOI":"10.1177\/2047487316653709","volume":"23","author":"MF Piepoli","year":"2016","unstructured":"Authors\/Task Force M, Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FD, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WM, Additional Contributor, Simone B, Document R, De Backer G, Roffi M, Aboyans V, Bachl N, Bueno H, Carerj S, Cho L, De Sutter J, Egidi G, Fisher M, Fitzsimons D, Franco OH, Guenoun M, Jennings C, Jug B, Kirchhof P, Kotseva K, Lip GY, Mach F, Mancia G, Bermudo FM, Mezzani A, Niessner A, Ponikowski B, Rauch B, Ryden L, Stauder A, Turc G, Wiklund O, Windecker S, Zamorano JL (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol 23(11):NP1-NP96. doi: 10.1177\/2047487316653709","journal-title":"Eur J Prev Cardiol"},{"issue":"23","key":"83_CR10","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A (2010) Lipoprotein(a) as a\u00a0cardiovascular risk factor: current status. Eur Heart\u00a0J 31(23):2844\u20132853. doi: 10.1093\/eurheartj\/ehq386","journal-title":"Eur Heart J"},{"issue":"4932","key":"83_CR11","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1126\/science.2530631","volume":"246","author":"G Utermann","year":"1989","unstructured":"Utermann G (1989) The mysteries of lipoprotein(a). Science 246(4932):904\u2013910","journal-title":"Science"},{"issue":"6","key":"83_CR12","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","volume":"129","author":"AV Khera","year":"2014","unstructured":"Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S (2014) Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). Circulation 129(6):635\u2013642. doi: 10.1161\/CIRCULATIONAHA.113.004406","journal-title":"Circulation"},{"issue":"4","key":"83_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/HCO.0b013e32832ac21a","volume":"24","author":"K Tziomalos","year":"2009","unstructured":"Tziomalos K, Athyros VG, Wierzbicki AS, Mikhailidis DP (2009) Lipoprotein a: where are we now? Curr Opin Cardiol 24(4):351\u2013357. doi: 10.1097\/HCO.0b013e32832ac21a","journal-title":"Curr Opin Cardiol"},{"issue":"7","key":"83_CR14","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/eci.12095","volume":"43","author":"A Kei","year":"2013","unstructured":"Kei A, Liberopoulos E, Tellis K, Rizzo M, Elisaf M, Tselepis A (2013) Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a\u00a0randomized pilot trial. Eur J Clin Invest 43(7):698\u2013707. doi: 10.1111\/eci.12095","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"83_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2013.08.013","volume":"231","author":"E Moutzouri","year":"2013","unstructured":"Moutzouri E, Liberopoulos EN, Tellis CC, Milionis HJ, Tselepis AD, Elisaf MS (2013) Comparison of the effect of simvastatin versus simvastatin\/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. Atherosclerosis 231(1):8\u201314. doi: 10.1016\/j.atherosclerosis.2013.08.013","journal-title":"Atherosclerosis"},{"issue":"4","key":"83_CR16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2796.1989.tb01393.x","volume":"226","author":"LA Carlson","year":"1989","unstructured":"Carlson LA, Hamsten A, Asplund A (1989) Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J\u00a0Intern Med 226(4):271\u2013276","journal-title":"J Intern Med"},{"issue":"9","key":"83_CR17","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0002-9149(00)00703-7","volume":"85","author":"A Goldberg","year":"2000","unstructured":"Goldberg A, Alagona P Jr., Capuzzi DM, Guyton J, Morgan JM, Rodgers J, Sachson R, Samuel P (2000) Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 85(9):1100\u20131105. doi:S0002-9149(00)00703-7","journal-title":"Am J Cardiol"},{"issue":"2","key":"83_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.atherosclerosis.2009.12.023","volume":"210","author":"E Bruckert","year":"2010","unstructured":"Bruckert E, Labreuche J, Amarenco P (2010) Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210(2):353\u2013361. doi: 10.1016\/j.atherosclerosis.2009.12.023","journal-title":"Atherosclerosis"},{"issue":"6","key":"83_CR19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0022-3565(25)08256-4","volume":"5","author":"A Jea","year":"1914","unstructured":"Abel J (1914) Plasma removal with return of corpuscles. J\u00a0Pharmacol Exp Ther 5(6):625\u2013641","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"83_CR20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/MOL.0b013e32833e13","volume":"21","author":"GR Thompson","year":"2010","unstructured":"Thompson GR (2010) Lipoprotein apheresis. Curr Opin Lipidol 21(6):487\u2013491. doi: 10.1097\/MOL.0b013e32833e13","journal-title":"Curr Opin Lipidol"},{"key":"83_CR21","first-page":"2561","volume":"109","author":"Bundesausschuss G","year":"2010","unstructured":"Bundesausschuss G (2010) Richtlinie des Gemeinsamen Bundesausschusses zu Untersuchungs- und Behandlungsmethoden der vertrags\u00e4rztlichen Versorgung. Bundesanz 109:2561","journal-title":"Bundesanz"},{"issue":"15\u201316","key":"83_CR22","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00508-015-0833-4","volume":"127","author":"K Derfler","year":"2015","unstructured":"Derfler K, Steiner S, Sinzinger H (2015) Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment. Wien Klin Wochenschr 127(15\u201316):655\u2013663. doi: 10.1007\/s00508-015-0833-4","journal-title":"Wien Klin Wochenschr"},{"issue":"10","key":"83_CR23","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.numecd.2010.04.007","volume":"20","author":"C Stefanutti","year":"2010","unstructured":"Stefanutti C (2010) The 2009 2nd Italian Consensus Conference on LDL-apheresis. Nutr Metab Cardiovasc Dis 20(10):761\u2013762. doi: 10.1016\/j.numecd.2010.04.007","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"83_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.atherosclerosis.2008.02.009","volume":"198","author":"GR Thompson","year":"2008","unstructured":"Thompson GR (2008) Recommendations for the use of LDL apheresis. Atherosclerosis 198(2):247\u2013255. doi: 10.1016\/j.atherosclerosis.2008.02.009","journal-title":"Atherosclerosis"},{"issue":"2","key":"83_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1744-9987.2009.00667.x","volume":"13","author":"S Bohl","year":"2009","unstructured":"Bohl S, Kassner U, Eckardt R, Utz W, Mueller-Nordhorn J, Busjahn A, Thomas HP, Abdel-Aty H, Klingel R, Marcovina S, Dietz R, Steinhagen-Thiessen E, Schulz-Menger J, Vogt A (2009) Single lipoprotein apheresis session improves cardiac microvascular function in patients with elevated lipoprotein(a): detection by stress\/rest perfusion magnetic resonance imaging. Ther Apher Dial 13(2):129\u2013137. doi: 10.1111\/j.1744-9987.2009.00667.x","journal-title":"Ther Apher Dial"},{"issue":"3","key":"83_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/ncpcardio1456","volume":"6","author":"BR Jaeger","year":"2009","unstructured":"Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, Parhofer K, Ramlow W, Koch M, Utermann G, Labarrere CA, Seidel D, Group of (2009) Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 6(3):229\u2013239. doi: 10.1038\/ncpcardio1456","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"2","key":"83_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/aor.12135","volume":"38","author":"A Rosada","year":"2014","unstructured":"Rosada A, Kassner U, Vogt A, Willhauck M, Parhofer K, Steinhagen-Thiessen E (2014) Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events? Artif Organs 38(2):135\u2013141. doi: 10.1111\/aor.12135","journal-title":"Artif Organs"},{"key":"83_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.atherosclerosissup.2015.02.006","volume":"18","author":"VJ Schettler","year":"2015","unstructured":"Schettler VJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Ramlow W, Blume H, Scientific Board of GftGAWG (2015) First data from the German Lipoprotein Apheresis Registry (GLAR). Atheroscler Suppl 18:41\u201344. doi: 10.1016\/j.atherosclerosissup.2015.02.006","journal-title":"Atheroscler Suppl"},{"issue":"1","key":"83_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.atherosclerosissup.2012.10.005","volume":"14","author":"M Dryander von","year":"2013","unstructured":"von Dryander M, Fischer S, Passauer J, Muller G, Bornstein SR, Julius U (2013) Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern. Atheroscler Suppl 14(1):39\u201344. doi: 10.1016\/j.atherosclerosissup.2012.10.005","journal-title":"Atheroscler Suppl"},{"issue":"1","key":"83_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.atherosclerosissup.2012.10.015","volume":"14","author":"MS Safarova","year":"2013","unstructured":"Safarova MS, Ezhov MV, Afanasieva OI, Matchin YG, Atanesyan RV, Adamova IY, Utkina EA, Konovalov GA, Pokrovsky SN (2013) Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl 14(1):93\u201399. doi: 10.1016\/j.atherosclerosissup.2012.10.015","journal-title":"Atheroscler Suppl"},{"issue":"24","key":"83_CR31","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","volume":"128","author":"J Leebmann","year":"2013","unstructured":"Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Maerz W, Lehmacher W, Heibges A, Klingel R, ProLiFe Study G (2013) Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 128(24):2567\u20132576. doi: 10.1161\/CIRCULATIONAHA.113.002432","journal-title":"Circulation"},{"issue":"9","key":"83_CR32","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","volume":"36","author":"E Roeseler","year":"2016","unstructured":"Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Leebmann J, Lehmacher W, Kamstrup PR, Nordestgaard BG, Maerz W, Noureen A, Schmidt K, Kronenberg F, Heibges A, Klingel R, ProLiFe-Study G (2016) Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization. Arterioscler Thromb Vasc Biol 36(9):2019\u20132027. doi: 10.1161\/ATVBAHA.116.307983","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7918","key":"83_CR33","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/s0140-6736(75)92193-5","volume":"1","author":"GR Thompson","year":"1975","unstructured":"Thompson GR, Lowenthal R, Myant NB (1975) Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1(7918):1208\u20131211. doi: 10.1016\/s0140-6736(75)92193-5","journal-title":"Lancet"},{"issue":"1","key":"83_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2013.05.012","volume":"230","author":"T Teramoto","year":"2013","unstructured":"Teramoto T, Shirakawa M, Kikuchi M, Nakagomi M, Tamura S, Surks HK, McCrary Sisk C, Numaguchi H (2013) Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia. Atherosclerosis 230(1):52\u201360. doi: 10.1016\/j.atherosclerosis.2013.05.012","journal-title":"Atherosclerosis"},{"issue":"9983","key":"83_CR35","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(14)62115-2","volume":"385","author":"JJ Kastelein","year":"2015","unstructured":"Kastelein JJ, Besseling J, Shah S, Bergeron J, Langslet G, Hovingh GK, Al-Saady N, Koeijvoets M, Hunter J, Johnson-Levonas AO, Fable J, Sapre A, Mitchel Y (2015) Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a\u00a0randomised, double-blind, placebo-controlled, phase 3 study. Lancet 385(9983):2153\u20132161. doi: 10.1016\/S0140-6736(14)62115-2","journal-title":"Lancet"},{"issue":"9992","key":"83_CR36","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","volume":"386","author":"GK Hovingh","year":"2015","unstructured":"Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, Rader DJ, Brewer HB, Barter PJ (2015) Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a\u00a0randomised, double-blind, placebo-controlled phase 2 trial. Lancet 386(9992):452\u2013460. doi: 10.1016\/S0140-6736(15)60158-1","journal-title":"Lancet"},{"key":"83_CR37","unstructured":"Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01252953"},{"issue":"9","key":"83_CR38","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","volume":"129","author":"DJ Rader","year":"2014","unstructured":"Rader DJ, Kastelein JJ (2014) Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 129(9):1022\u20131032. doi: 10.1161\/CIRCULATIONAHA.113.001292","journal-title":"Circulation"},{"key":"83_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/CE.S25239ce-7-029","volume":"7","author":"KG Parhofer","year":"2012","unstructured":"Parhofer KG (2012) Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. Core Evid 7:29\u201338. doi: 10.2147\/CE.S25239ce-7-029","journal-title":"Core Evid"},{"issue":"9719","key":"83_CR40","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","volume":"375","author":"FJ Raal","year":"2010","unstructured":"Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a\u00a0randomised, double-blind, placebo-controlled trial. Lancet 375(9719):998\u20131006. doi: 10.1016\/S0140-6736(10)60284-X","journal-title":"Lancet"},{"issue":"19","key":"83_CR41","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","volume":"126","author":"EA Stein","year":"2012","unstructured":"Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, Chin W, Tribble DL, McGowan M (2012) Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a\u00a0randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 126(19):2283\u20132292. doi: 10.1161\/CIRCULATIONAHA.112.104125","journal-title":"Circulation"},{"issue":"6","key":"83_CR42","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1517\/14656566.2013.779253","volume":"14","author":"A Vogt","year":"2013","unstructured":"Vogt A, Parhofer KG (2013) The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease. Expert Opin Pharmacother 14(6):691\u2013697. doi: 10.1517\/14656566.2013.779253","journal-title":"Expert Opin Pharmacother"},{"issue":"9860","key":"83_CR43","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","volume":"381","author":"M Cuchel","year":"2013","unstructured":"Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, Averna MR, Sirtori CR, Shah PK, Gaudet D, Stefanutti C, Vigna GB, Du Plessis AM, Propert KJ, Sasiela WJ, Bloedon LT, Rader DJ, Phase 3 Ho FHLSi (2013) Efficacy and safety of a\u00a0microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a\u00a0single-arm, open-label, phase 3 study. Lancet 381(9860):40\u201346. doi: 10.1016\/S0140-6736(12)61731-0","journal-title":"Lancet"},{"issue":"12","key":"83_CR44","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH Jr., Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N\u00a0Engl J Med 354(12):1264\u20131272. doi: 10.1056\/NEJMoa054013","journal-title":"N Engl J Med"},{"key":"83_CR45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501031","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, Shahawy ME, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ, Investigators OLT (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N\u00a0Engl J Med. doi: 10.1056\/NEJMoa1501031","journal-title":"N Engl J Med"},{"key":"83_CR46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500858","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Open-Label Study of Long-Term Evaluation against LDLCI (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N\u00a0Engl J Med. doi: 10.1056\/NEJMoa1500858","journal-title":"N Engl J Med"},{"issue":"13","key":"83_CR47","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","volume":"63","author":"FJ Raal","year":"2014","unstructured":"Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman SM, Huang F, Xue A, Albizem M, Scott R, Stein EA (2014) Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a\u00a0pooled analysis of more than 1,300 patients in 4 phase II trials. J\u00a0Am Coll Cardiol 63(13):1278\u20131288. doi: 10.1016\/j.jacc.2014.01.006","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"83_CR48","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","volume":"114","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, Kereiakes DJ, McKenney JM, Roth EM, Hanotin C, Gipe D, Du Y, Ferrand AC, Ginsberg HN, Stein EA (2014) Effect of alirocumab, a\u00a0monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150\u202fmg every two weeks dosing from phase 2 trials). Am J Cardiol 114(5):711\u2013715. doi: 10.1016\/j.amjcard.2014.05.060","journal-title":"Am J Cardiol"},{"issue":"9965","key":"83_CR49","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA, Investigators T (2015) Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a\u00a0randomised, double-blind, placebo-controlled trial. Lancet 385(9965):341\u2013350. doi: 10.1016\/S0140-6736(14)61374-X","journal-title":"Lancet"},{"issue":"9","key":"83_CR50","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.113.001969","volume":"128","author":"NR Desai","year":"2013","unstructured":"Desai NR, Kohli P, Giugliano RP, O\u2019Donoghue ML, Somaratne R, Zhou J, Hoffman EB, Huang F, Rogers WJ, Wasserman SM, Scott R, Sabatine MS (2013) AMG145, a\u00a0monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C assessment with proprotein convertase subtilisin kexin type 9 monoclonal antibody inhibition combined with statin therapy (LAPLACE)-thrombolysis in myocardial infarction (TIMI) 57 trial. Circulation 128(9):962\u2013969. doi: 10.1161\/CIRCULATIONAHA.113.001969","journal-title":"Circulation"},{"key":"83_CR51","volume-title":"Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor","author":"Pfizer","year":"2016","unstructured":"Pfizer (2016) Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor. Pfizer, New York"},{"key":"83_CR52","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ahj.2015.11.015","volume":"173","author":"MS Sabatine","year":"2016","unstructured":"Sabatine MS, Giugliano RP, Keech A, Honarpour N, Wang H, Liu T, Wasserman SM, Scott R, Sever PS, Pedersen TR (2016) Rationale and design of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk trial. Am Heart\u00a0J 173:94\u2013101. doi: 10.1016\/j.ahj.2015.11.015","journal-title":"Am Heart J"},{"issue":"5","key":"83_CR53","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","volume":"168","author":"GG Schwartz","year":"2014","unstructured":"Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG (2014) Effect of alirocumab, a\u00a0monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart\u00a0J 168(5):682\u2013689. doi: 10.1016\/j.ahj.2014.07.028","journal-title":"Am Heart J"},{"issue":"15","key":"83_CR54","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.jacc.2010.10.052","volume":"57","author":"E Merki","year":"2011","unstructured":"Merki E, Graham M, Taleb A, Leibundgut G, Yang X, Miller ER, Fu W, Mullick AE, Lee R, Willeit P, Crooke RM, Witztum JL, Tsimikas S (2011) Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J\u00a0Am Coll Cardiol 57(15):1611\u20131621. doi: 10.1016\/j.jacc.2010.10.052","journal-title":"J Am Coll Cardiol"},{"issue":"10002","key":"83_CR55","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","volume":"386","author":"S Tsimikas","year":"2015","unstructured":"Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, Burkey JL, Yang Q, Marcovina SM, Geary RS, Crooke RM, Witztum JL (2015) Antisense therapy targeting apolipoprotein(a): a\u00a0randomised, double-blind, placebo-controlled phase 1 study. Lancet 386(10002):1472\u20131483. doi: 10.1016\/S0140-6736(15)61252-1","journal-title":"Lancet"}],"container-title":["Clinical Research in Cardiology Supplements"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11789-017-0083-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11789-017-0083-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11789-017-0083-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T04:49:15Z","timestamp":1749962955000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11789-017-0083-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,9]]},"references-count":55,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["83"],"URL":"https:\/\/doi.org\/10.1007\/s11789-017-0083-2","relation":{},"ISSN":["1861-0706","1861-0714"],"issn-type":[{"value":"1861-0706","type":"print"},{"value":"1861-0714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,9]]}}}